REVIEW Delapril, a nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, is used for the treatment of hypertension in a number of European and Asian countries. Delapril has an indanylglycine moiety differing from the proline moiety of captopril or enalapril, is an esterified prodrug that is converted in vivo to its active metabolite, an 5-hydroxy-indane diacid.
Shionoiri H; Yasuda G; Ikeda A; Ohta T; Miyajima E; Kaneko Y; Pharmacokinetics and depressor effect of delapril in patients with essential hypertension. Clinical pharmacology and therapeutics (1987), 41(1), 74-9.
Saito S; Matsui S; Fukushima S; Watanabe M; Waga T; Kajiwara Y; Shirota M; Iijima M; Kitabatake K; Synthesis and angiotension converting enzyme inhibitory activity of L-lysyl-N-substituted glycine derivatives Arzneimittel-Forschung (1989), 39(12), 1558-61.
Saruta T, Nishikawa K. Characteristics of a new angiotensin converting enzyme inhibitor: delapril. Am J Hypertens. 1991 Jan;4(1 Pt 2):23S-28S.
Razzetti R, Acerbi D. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor. Am J Cardiol. 1995 Jun 16;75(18):7F-12F.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.